Arcus Biosciences, Inc. (RCUS)

NYQ – Real vaqt narxi. Valyuta: USD

31.00

+0.75 (2.48%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

31.36

+0.36 (1.16%)

Bozordan keyin: Jun 26, 2026, 5:57 PM EDT

10.06.2026

Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $23.32, which was the.

04.06.2026

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

03.06.2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

26.05.2026

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast o.

06.05.2026

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

05.05.2026

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.14 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

09.06.2026

Arcus Biosciences Announces New Employment Inducement Grants

03.06.2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

05.05.2026

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “Arcus is entering a new era, with a clear path for casdatif.

24.04.2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Company's common stock at an exercise price per share of $25.13, which was the.

Arcus Biosciences, Inc. (RCUS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Arcus Biosciences Announces New Employment Inducement Grants

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Arcus Biosciences Announces New Employment Inducement Grants

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Search stocks

Arcus Biosciences, Inc. (RCUS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Arcus Biosciences Announces New Employment Inducement Grants

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Arcus Biosciences Announces New Employment Inducement Grants

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants